Towards Photochromic Azobenzene‐Based Inhibitors for Tryptophan Synthase by Simeth, Nadja Anita et al.
& Antibiotics
Towards Photochromic Azobenzene-Based Inhibitors for
Tryptophan Synthase
Nadja A. Simeth+,*[a, b] Thomas Kinateder+,[c] Chitra Rajendran,[c] Julian Nazet,[c] Rainer Merkl,[c]
Reinhard Sterner,[c] Burkhard Kçnig,[a] and Andrea C. Kneuttinger*[c]
Abstract: Light regulation of drug molecules has gained
growing interest in biochemical and pharmacological re-
search in recent years. In addition, a serious need for novel
molecular targets of antibiotics has emerged presently.
Herein, the development of a photocontrollable, azoben-
zene-based antibiotic precursor towards tryptophan syn-
thase (TS), an essential metabolic multienzyme complex in
bacteria, is presented. The compound exhibited moderately
strong inhibition of TS in its E configuration and five times
lower inhibition strength in its Z configuration. A combina-
tion of biochemical, crystallographic, and computational
analyses was used to characterize the inhibition mode of
this compound. Remarkably, binding of the inhibitor to a
hitherto-unconsidered cavity results in an unproductive con-
formation of TS leading to noncompetitive inhibition of tryp-
tophan production. In conclusion, we created a promising
lead compound for combatting bacterial diseases, which tar-
gets an essential metabolic enzyme, and whose inhibition
strength can be controlled with light.
Introduction
Antibiotics are crucial for modern medicine.[1] They are used to
cure bacterial illnesses and infections, and to facilitate major
surgical operations. Most of us have used them at least once
in our lives. To further our understanding of their mode of
action, antibiotic precursors are often designed for biochemical
and pharmaceutical studies. This ultimately paves the way for
drugs that are highly efficient, specific, and less prone to build-
up of resistance. In particular, focusing on novel types of mac-
romolecular targets and innovative strategies to circumvent re-
sistance are paramount to this cause.[2]
Most antibiotics engage in bacterial cell-division processes
or weaken the bacterial membrane.[3] Recently, the search for
alternative targets was expanded to metabolic enzymes,[4] such
as the well-investigated multienzyme complex tryptophan syn-
thase (TS). TS catalyzes the last two steps of tryptophan bio-
synthesis in bacteria, plants, and fungi.[5] The complex consists
of TrpA (a) and TrpB (b), which are arranged as a heterotetram-
er in a linear abba configuration.[6] The functional unit of TS is
thereby formed by one ab heterodimer (Figure 1 A).[7] Trypto-
phan production starts with the TrpA reaction, in which indole-
3-glycerol phosphate (IGP) is cleaved in a retro-aldol reaction
to glyceraldehyde 3-phosphate (GAP) and indole.[7] In the next
step, indole travels through an intermolecular channel to the
active site of TrpB,[8] where it is used to synthesize tryptophan
from serine by using pyridoxal phosphate (PLP) as a cofac-
tor.[5b, 9] Both reactions, indole synthesis in TrpA and tryptophan
synthesis in TrpB, require tight allosteric regulation of both
subunits (Figure 1 B).[6a, 10] On binding of IGP in the TrpA active
site, the affinity for serine in the TrpB active site is enhanced,
as shown by a reduced K SerM value, so that the initial reaction of
serine with PLP to an aminoacrylate intermediate is facilitat-
ed.[8] The formation of the aminoacrylate in turn enhances the
turnover of IGP to indole, as manifested in an increased kcat
value of TrpA.[11] Structural analysis of TS from Salmonella typhi-
murium revealed that a conformational change of the commu-
nication (COMM) domain, which includes around 90 residues
in TrpB, is in particular responsible for the propagation of the
allosteric signals between the two active sites.[12] In the ab-
sence of IGP and serine, the COMM domain exhibits an open
conformation, while binding of IGP in TrpA and the subse-
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quent formation of aminoacrylate in TrpB induce a stepwise
transition to a closed conformation.[12b, 13] As mammals lack the
genes for the biosynthetic pathway of tryptophan, TS repre-
sents an excellent target for the development of new antibiot-
ics. Previous studies already reported inhibitors towards TS
that compete with IGP for the active site of TrpA,[14] bind at
the TrpA:TrpB interface,[15] or interact with the hydrophobic in-
termolecular indole channel in TrpB.[16] These examples provide
good starting points for the development of antibiotic agents.
Direct control of the efficacy of drugs is an innovative ap-
proach in biochemical and pharmacological studies, which is
increasingly used to gain in depth knowledge of the mode of
action. Temporally resolved activation allows one to unambigu-
ously associate the observed effect to the drug. Most recently,
the spatiotemporal control of drugs has been addressed by de-
veloping light-responsive, bioactive molecules in the growing
field of photopharmacology.[17] Besides many other applica-
tions, such as photosensitive proteins,[18] DNA modulators,[19]
kinase inhibitors,[20] and PROTAGs,[21] the first photocontrollable
antibiotics have been developed.[22] The principle of photo-
pharmacology is based on a seemingly simple strategy; the de-
signed drug consists of moieties that convey a biological re-
sponse, such as an inhibitory effect toward the target struc-
ture, and a photoresponsive part that facilitates a light-induced
structural change. Thus, the drug is rendered effective in one
configuration and ineffective in the other. Moreover, the differ-
ent photoisomers can exhibit different pharmacokinetic and
pharmacodynamic properties. A frequently used photoactuator
is azobenzene, a molecule consisting of two aryl units connect-
ed by a diazo bond (N=N). On irradiation with light of a specif-
ic wavelength, the thermodynamically more stable E isomer
can be converted to its corresponding Z form. This configura-
tional change affects several properties of the molecule includ-
ing its UV/Vis absorption spectrum, its steric demand, its polar-
ity, and, if embedded in a suitable bioactive structure, its affini-
ty towards, for example, enzymes. The metastable Z isomer
can be converted back to the E form by irradiation with light
of lower energy or thermally.[23]
In recent years, we have pioneered the control of metabolic
multienzyme complexes with diverse photoresponsive tools.[24]
In the present work, we explored photocontrollable inhibitors
for the essential multienzyme complex TS of the enteric
human pathogen S. typhimurium[25] as potential antibiotic
structures. We designed and synthesized a small library of azo-
benzene-based compounds, investigated their photochemical
behavior, and thoroughly studied their mode of inhibition to-
wards TS. Finally, we substantiated these findings with crystal-
lographic and computational methods and outline a mode of
action for this potential drug precursor.
Figure 1. Schematic representation of the tryptophan synthase (TS) functional unit, its reactions, and allosteric regulation. A) In TrpA (orange) indole-3-glycerol
phosphate (IGP) is cleaved into glyceraldehyde 3-phosphate (GAP) and indole, which is channeled through a hydrophobic tunnel (white) to TrpB (cyan). In
TrpB, pyridoxal phosphate, bound as internal aldimine (IA), reacts with serine (Ser) to form aminoacrylate (AA), which subsequently reacts with indole to the
final product tryptophan (Trp). The communication (COMM) domain of TrpB is shown in dark blue. B) In the absence of serine and IGP, TS is inactive and the
COMM domain in TrpB adopts an open conformation (1). Binding of IGP to the TrpA active site leads to a partial closure of the COMM domain and an alloste-
ric activation of TrpB enhancing the binding affinity (KMfl) for its substrate serine (2). The formation of AA from PLP and serine in TrpB results in a fully closed
COMM domain and an allosteric activation of TrpA, which increases the turnover of IGP to indole (Ind) and GAP (kcat›, 3). Finally, Trp, the reaction product of
AA and Ind, dissociates from TrpB, and the COMM domain returns to its inactive open conformation (4).[13c]
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Design and molecular realization
Previous studies have described various target sites for inhibi-
tors in the TS complex.[14b, c, 15, 16] We reasoned that targeting
the TrpA active site is a good starting point for the design of a
photocontrollable inhibitor. Hence, we analyzed the crystal
structures of TS with IGP or the inhibitor indole-3-propanol
phosphate bound to TrpA[6c, 12a] to identify the most important
ligand–enzyme interactions and steric requirements for bind-
ing to the active site (Figure S1.1 in the Supporting Informa-
tion). Since both ligands form strong hydrogen bonds to resi-
dues in the active site with their phosphate motif and their NH
moiety (Figure 2 A), we integrated these two groups into our
inhibitor design.
Consequently, our synthetic ligands consist of a phosphate
motif to which an NH-containing amide moiety is attached
through an alkyl linker (Figure 2 B). To allow for reversible pho-
toswitching, we extended the binding part of the molecule
with an azobenzene photoswitch attached to the carbonyl
group.[26] Finally, we varied the length of the alkyl or aryl linker
to find an inhibitor that exhibits the optimal geometry to bind
to the TrpA active site in one but not in the other photoisom-
er. Furthermore, we hypothesized that the E isomers would
show stronger binding, whereas the increased steric demand
in the Z isomers should lead to weaker binding. Following this
assumption, the inhibitors in E should competitively displace
IGP and inhibit the TrpA reaction, while the Z isomer should
allow for IGP binding and turnover. As a result, due to the
strong dependence of the TrpB reaction on binding of IGP to
the TrpA active site, we would be able to simultaneously con-
trol IGP turnover in TrpA, and tryptophan production in TrpB
with light (Figure 2 C).
Synthesis
For the synthesis of a small library of azobenzene-based inhibi-
tors as defined in our design (Figure 2 B), we started from com-
mercially available 4-carboxyazobenzene (1, Scheme 1). We
converted the carboxylic acid, by treatment with SOCl2, to the
corresponding acyl chloride 2, which was directly treated with
differently functionalized amines to give 3 a–f (3–31 % yield).
As main side reaction, we found chlorination of the arene
moiety of the azobenzene, as shown by XRD in a related work
(CCDC 1873980). In the last step, the compounds were treated
with POCl3 in the presence of 1,8-bis(dimethylamino)naphtha-
lene (proton sponge) as base to functionalize the alcohol
group. On aqueous workup, hydrolysis of the phosphorus chlo-
ride resulted in the corresponding phosphate derivatives 4 a–f.
Figure 2. Design of azobenzene inhibitors of TS by the azo-extension approach. A) Binding of IGP to the active site of TrpA is mainly facilitated by two moiet-
ies. The phosphate group (cyan) interacts with the NH groups of the peptide backbone of Gly184, Gly213, Gly234, and Ser235, as well as with the side chain
of Ser235. The NH group (orange) forms hydrogen bonds to the sidechain of Asp60. Gray lines indicate the dimensions of the binding pocket. B) The two
main binding motifs of IGP, the phosphate and NH groups, were integrated in the design of azo-extended TS inhibitors. The phosphate group was installed
at varying distances to an amide through an aryl or alkyl linker. This biologically active module was then extended with an azo moiety that switches configu-
rations (EQZ ; indicated by differently shaped green boxes) on irradiation with UV (365 nm) or visible (420 nm) light. While the E isomers are expected to bind
similar to the native substrate, steric hindrance between inhibitor and binding pocket (gray) is expected to prevent binding of the Z isomers. C) By displacing
IGP (red ellipse) from TrpA with the light-switchable azobenzene inhibitor (green box), TrpA is competitively inhibited and TrpB is deprived of its substrate
indole. On irradiation with UV light, the Z isomer is formed. Due to its higher steric demand, we expect the Z isomer to show a lower binding affinity, and
thus TrpA and TrpB activity is restored. This step is reversed by irradiation with visible light.
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After preparative HPLC purification, the compounds were iso-
lated as orange solids. Unconverted starting material and
losses during HPLC purification resulted in only low (0.2 %) to
moderate (37 %) yields. Nevertheless, we obtained enough ma-
terial for photophysical and photochemical studies as well as
for screening of the compounds in a biochemical assay.
Photophysical and photochemical characterization
We next assessed the solubility and switching properties of
our inhibitors in aqueous solution to ensure compatibility with
the buffer system of our target enzyme TS. Compounds
4 a,b,d–f proved to be soluble, and were hence further charac-
terized with UV/Vis spectroscopy in water (Figures S5.1–5.6 in
the Supporting Information); the spectra of 4 e are shown rep-
resentatively in Figure 3. Spectra were recorded at thermal
equilibrium (black line), after irradiation with UV light of
365 nm (orange line), and after additional irradiation with visi-
ble light of 420 nm (green line).
At thermal equilibrium, each compound exhibited a main
absorbance maximum between 324 and 331 nm (Table 1),
which was assigned to the pp* transition of the E isomer.[23]
On irradiation with 365 nm light, the photostationary state
PSS365nm formed; the signal of the E isomer decreased and si-
multaneously an absorbance maximum between 423 and
428 nm emerged, which was attributed to the np* transition
of the Z isomer. The photostationary state distributions
(PSD365nm) were calculated by peak deconvolution with Gaussi-
an functions and showed that all compounds accumulated 64–
88 % of the Z isomer. Moreover, the metastable Z isomer was
found to be sufficiently stable for our measurements (vide
infra), as we determined a thermal lifetime of 3.76 d for com-
pound 4 e (Figure S5.7 in the Supporting Information). Subse-
quent irradiation with visible light of 420 nm wavelength in-
duced photochemical Z!E isomerization to PSS420nm. However,
the composition of the thermal equilibrium could not be fully
regenerated—all compounds only accumulated 71–92 % of the
E isomer (PSD420nm)—probably due to overlap of the np* band
of the E and the np* band of the Z isomer.[23]
Evaluation of the inhibition mode
To analyze the inhibitory potential of our compounds, we first
determined the concentration range in which the azobenzenes
inhibited the overall TS reaction (IGP + Ser!Trp + GAP). We
Scheme 1. Synthetic approach to photochromic TS ligands. a : SOCl2, 80 8C, 2 h (not isolated). b : 4-(2-Hydroxyethyl)aniline or suitable amino alcohol (1 equiv),
dry pyridine/dry CHCl3 (1:5), RT, 16 h, 3–31 %. c : method I: 1) proton sponge (3 equiv), POCl3, dry THF/dry CHCl3, 0 8C to RT, 2 h; 2) acetone/water (1:1), 0.2–7 %
(4 a,b,d,f) ; method II : 1) proton sponge (3 equiv), POCl3, PO(OMe)3, 0 8C to RT, 2 h; 2) acetone/water (1:1), 0.5–37 % (4 c,e).
Figure 3. UV/Vis spectra of compound 4 e (65 mm) in water. The black line
depicts the absorbance spectrum of the azobenzene-based inhibitor at its
thermal equilibrium. The orange line represents the PSS after irradiation
with light of 365 nm, and the green line shows the photostationary state
after irradiation with light of 420 nm. The photostationary distribution is
shown next to each line.
Table 1. Overview of photophysical and photochemical properties of
compounds 4 a,b,d–f in water.[a]
Compound lmax (pp* of E) [nm] lmax (np*of Z) [nm] PSD
365nm PSD420nm
4 a 331 423 36E :64Z 92E :8Z
4 b 324 427 20E :80Z 71E :29Z
4 d 326 428 21E :79Z 90E :10Z
4 e 324 427 12E :88Z 88E :12Z
4 f 325 427 15E :85Z 84E :16Z
[a] PSDs were determined by extraction of the PSS by UV/Vis spectrosco-
py through peak deconvolution with Gaussian functions;[27] for details,
see Figures S5.1–5.6 of the Supporting Information.
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measured TS activity by monitoring tryptophan production in
a recently established coupled enzymatic assay[24c] in the pres-
ence of compounds 4 a,b,d–f in their E or Z (referring to
PSS365nm) configuration. Inhibitor concentrations were gradually
increased, whereas the IGP and serine concentrations were
kept constant at 30 mm (KM[24c]) and 5 mm (saturated[24c]), re-
spectively. Compounds 4 d–f showed 30–70 % inhibition in the
low millimolar range (0.1–0.25 mm, Figure S6.1 in the Support-
ing Information). Compounds 4 a and 4 b, on the other hand,
were not able to inhibit TS at soluble concentrations and were
therefore excluded from further analyses.
We then quantified the inhibitory effect of compounds 4 d–f
in their E and Z configurations. Since we designed our inhibi-
tors as IGP analogues, we expected a competitive mode of in-
hibition towards the TrpA substrate (Figure 2 C). Hence, we
monitored IGP saturation curves for the overall TS reaction in
the presence of different inhibitor concentrations. Inhibitor
concentrations were chosen from the previous measurements
and corresponded to 0 % (0 mm), 30 % (0.1 mm), 50 %
(0.175 mm), and 70 % (0.25 mm) inhibition. For each IGP satu-
ration curve, an apparent Michaelis constant K appM and an ap-
parent rate constant kappcat were determined (Figure S6.2,
Table S6.1 in the Supporting Information). Competitive inhibi-
tion is characterized by a decreased K appM value and an un-
changed kappcat value; however, we observed unchanged K
app
M
values and decreased kappcat values for all our compounds, and
this indicates that the inhibitors did not compete with IGP for
the TrpA active site.
To identify the actual mode of inhibition, we performed
global fits using Equation (2) (vide infra) of the four IGP satura-
tion curves for each inhibitor. Thus, we obtained the factor for
inhibitor modality a, which indicates the mode of inhibition,
and the inhibition constant Ki, which describes the strength of
inhibition, for the inhibitors 4 d–f in their E and Z configura-
tions. All compounds exhibited finite a factors indicative of a
noncompetitive mode of inhibition[28] (Figure S6.2 in the Sup-
porting Information, Table 2), which confirmed our conclusion
that the azobenzene inhibitors did not compete with IGP for
the TrpA active site. Although the compounds did not exhibit
the intended inhibition mode, they nonetheless had Ki values
in the low millimolar range (Table 2). In particular, com-
pound 4 e stood out with Ki values of only 0.18 mm for its E
isomer and 0.93 mm for its Z isomer, which correspond to a
light regulation factor (LRF) of approximately five. In compari-
son to 4 e, the inhibitory strength of 4 d was four times
weaker, represented by a higher Ki value, and the LRF of 4 f
was 2.5 times lower. Compound 4 e was consequently chosen
as the best candidate for the reversible light-sensitive inhibi-
tion of TS, as it combines good inhibitory strength with a high
potential for light regulation.
We further tested whether the azobenzene inhibitors might
associate with the hydrophobic binding site of indole in TrpB
instead of the active site of TrpA. Hence, we measured the
TrpB reaction (indole + Ser!Trp) with varying concentrations
of indole and saturating concentrations of serine in the pres-
ence of our best inhibitor 4 e. The K appM , k
app
cat , Ki, and a values
were determined accordingly (Figure S6.3, Table S6.2 in the
Supporting Information). Similar to the inhibition studies with
IGP, the K appM values remained unchanged, whereas the k
app
cat
values decreased with increasing inhibitor concentrations. Con-
sistently, the a factors for both isomers were finite (0.7), indi-
cating that compound 4 e does not compete with indole for
binding at the TrpB active site. Furthermore, 4 e showed Ki
values of approximately 0.18 mm for its E isomer and approxi-
mately 0.50 mm for its Z isomer, corresponding to an LRF of
approximately three, comparable to the measurements with
IGP. These results demonstrate that the inhibitory mode of our
light-switchable azobenzene inhibitors is also noncompetitive
towards the TrpB active site.
In conclusion, other than originally intended, our synthe-
sized azobenzene-based compounds led to noncompetitive in-
hibition of TS activity. Nevertheless, inhibition strength could
still be light-regulated for all our inhibitors by a factor of 2–6.
The E configuration conferred a stronger inhibitory effect sug-
gesting that this isomer associates more easily with the TS
complex than the sterically more demanding Z isomer. More-
over, increasing length of the alkyl linker in 4 d–f resulted in in-
creasingly stronger inhibition; however, it also reduced the po-
tential for light-responsive inhibition. Our best inhibitor 4 e
showed both a relatively large inhibition constant for the E
isomer of 0.18 mm and a relatively high LRF. Previously report-
ed TS inhibitors that bind at the TrpA active site or close to
the protein interface showed high or even ultrahigh inhibition
strengths with Ki values of 4.8 mm
[29] and 40 nm,[16] respectively.
In comparison, 4 e only shows medium-strength inhibition,
which is expected to have at best a slightly harmful effect on
bacteria. However, taking into account that this inhibitor was
not designed for a noncompetitive inhibition mode, inhibition
in the low millimolar range is still noteworthy. We reasoned
that, by identifying the exact binding site of 4 e, we might be
able to optimize the structure of this lead compound, and
hence its inhibition strength, in future studies.
Cocrystallization of TS with azobenzene inhibitor 4 e
For identification of the binding site of 4 e in the TS complex,
we performed cocrystallization experiments. To ensure that TS
Table 2. Inhibition values (a, Ki) and light-regulation factors for the IGP-
and serine-dependent reaction of TS with compounds 4 d–f in their E and
Z configurations.














[a] E refers to the compound at the thermal equilibrium containing ap-
proximately 100 % E isomer. [b] Z refers to the compound with the Z-en-
riched PSD after irradiation with UV light. [c] LRF = light-regulation factor.
Values for Ki standard error were determined by fitting the substrate
saturation curves for four different inhibitor concentrations (Figure S6.2 in
the Supporting Information) with Equation (2) (vide infra).
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was uniformly loaded with 4 e in the crystallization setup, we
first determined the binding constant KD of the inhibitor to the
TS complex. Isothermal titration calorimetry (ITC) provided a KD
value of approximately 67 mm indicating strong binding of 4 e
to the TS complex (Figure S7.1 in the Supporting Information).
Additionally, we measured the KD values of 4 e to the isolated
subunits, obtaining KD values of approximately 130 mm for
TrpA and approximately 10 mm for TrpB (Figures S7.2 and S6.3
in the Supporting Information). Thus, 4 e binds to TrpB with
significantly higher affinity. We therefore expected that the
binding site of 4 e was located in the TrpB subunit. Following
this analysis, we crystallized the TS complex in the presence of
4 e at saturated concentration (750 mm) and in excess (ca.
twofold) over the enzyme and solved its structure (TS4e) with
approximately 2.5  resolution (PDB-ID: 7A20; Table S7.1 in the
Supporting Information). The TS4e structure contained two
chain pairs of the functional unit of TS per unit cell. Since crys-
tallization took several weeks, we expected to find the E
isomer instead of the thermally unstable Z isomer of 4 e (vide
supra). However, no electron density could be assigned to the
inhibitor. The high binding affinity of 4 e to the TS complex
and the high concentrations used for the crystallization experi-
ments led to the conclusion that 4 e was bound to the TS com-
plex but could not be resolved, which suggested highly dy-
namic behavior of 4 e in the binding site.
We compared TS4e with an active conformation and an inac-
tive conformation of TS to identify potential structural changes
induced by 4 e (Figure 4). In the structure of the active TS
(TSAA ; blue)
[13a] an IGP analogue is bound to TrpA, the aminoa-
crylate intermediate is bound to TrpB, and the COMM domain
adopts a “closed” conformation. In the structure of the inactive
TS (TSIA ; gray),
[30] internal aldimine is bound to TrpB, and the
COMM domain adopts an “open” conformation. In TS4e (red),
no significant structural differences were found in the TrpA
subunit and the core structure of the TrpB subunit (Figure 4 A).
However, the COMM domain is even further shifted towards
an “extended-open” conformation (Figure 4 B). Notably, the
PLP cofactor was missing in the TrpB active site, and instead a
single buffer molecule was detected, that is, the TrpB active
site is exposed to solvent.
These findings suggest that 4 e holds the TS complex in an
unproductive conformation defined by an extended-open
COMM domain. Similar observations were made by Arnold and
co-workers in their studies on TS from Pyrococcus furiosus.
They found that a single molecule of b-methyl tryptophan
bound to a solvent-accessible binding cleft close to the TrpB
active site led to an extended-open state,[31] that is, the COMM
domain was shifted away from the protein core, similar to our
extended-open conformation induced by 4 e. This conforma-
tion of the COMM domain in TS4e most likely prohibits the allo-
steric communication between the two active sites and ren-
ders both enzymes inactive. In addition, access to the TrpB
active site is opened by the inhibitor, so that it is unprotected
against entry of solvent. These effects of 4 e on the TS struc-
ture explain the noncompetitive mode of inhibition. However,
it is still unclear where the binding site of the inhibitor is locat-
ed and how the inhibitor causes these changes. Since 4 e
showed the highest affinity toward the TrpB subunit in binding
studies, and since it strongly affected the COMM domain and
the TrpB active site in crystallization studies, we continued to
search for the binding site in the TrpB subunit by a computa-
tional approach.
Computational analysis of the putative inhibitor binding
site
Even though electron density cannot be detected when a
ligand is too dynamic, the binding site can still be traced by
identifying pockets in the protein structure that are large
enough to accommodate the ligand. Therefore, we analyzed
the structures of TSAA, TSIA, and TS4e with the software tool
Mole2.5.[32] In TSAA, in which the COMM domain exhibits a
closed conformation, no significantly large pockets could be
found (Figure S8.1.A in the Supporting Information). However,
in TSIA, in which the COMM domain takes on an open confor-
mation, we identified a surface-accessible cavity with a length
of approximately 25 , located in the cleft between the COMM
domain and the TrpB active site (Figure S8.1.B–C in the Sup-
porting Information). Finally, in TS4e, in which the COMM
domain is extended-open, we also found a cavity at the same
location as in TSIA but slightly enlarged with a length of ap-
proximately 29  (Figure 5 A). This cavity matches the dimen-
sions of the inhibitor (length 21 ) and exists in both TrpB
chains of TS4e with highly similar size and shape. Binding of
our inhibitor to this potential binding site could explain the
highly impaired structure of TS4e with the COMM domain in an
extended-open conformation. Remarkably, b-methyl trypto-
phan was also bound very close to this binding site when in-
ducing the extended-open state of TS in previous studies, and
this suggests that this site might be a novel allosteric binding
site of TS.[31] In agreement with this, binding of 4 e led to a
Figure 4. Structural comparison of TS in the presence of 4 e (red; PDB-ID:
7A20, chain pair AB) with the fully active aminoacrylate bound TSAA (blue;
PDB-ID: 2J9X, chain pair AB), and the inactive internal aldimine bound TSIA
(gray; PDB-ID: 1BKS, chain pair AB). A) Superposition of the three structures.
No structural differences were observed in the TrpA subunit (top, transpar-
ent) and the core of the TrpB subunit (bottom). B) 4 e induced significant
conformational changes in the COMM domain. While the COMM domain
adopts a closed conformation in TSAA (blue) and an open conformation in
TSIA (gray), it is extended-open in the presence of 4 e (red).
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noncompetitive mode of inhibition with respect to both the
TrpA and TrpB active sites. To the best of our knowledge, this
binding site has so far been unexplored in inhibition studies.
Two other groups described similarly allosteric inhibitors, but
their binding site is located within the indole channel and
closer to the TrpA:TrpB interface.[15, 16]
Continuing our computational examination, we tested
whether 4 e could sterically fit into this cavity and interact with
the lining residues. To this end, we performed a docking analy-
sis using YASARA.[33] In this experiment, the protein conforma-
tion was kept fixed, while the inhibitor was docked with full
conformational freedom. As a result, 17 binding geometries
could be identified for the inhibitor, out of which ten had pre-
dicted KD values below 5 mm (Table S8.1, Figure S8.2, Fig-
ure S8.3 in the Supporting Information). Remarkably, the orien-
tation of 4 e in most of the binding geometries differed signifi-
cantly, as illustrated by two exemplary orientations in Fig-
ure 5 B and C, which exhibited predicted KD values of 0.5 and
2.0 mm. In these examples, the phosphate group is buried at
the deep end of the cavity (Figure 5 B) or points towards the
surface of the protein (Figure 5 C). This variety of putative in-
hibitor geometries in the binding pocket confirms a highly dy-
namic binding behavior of 4 e, and is therefore consistent with
the lack of electron density in the crystal structure.
Photocontrolling the noncompetitive inhibition of TS
Our findings showed that inhibitor 4 e, which was originally
designed to associate at the TrpA active site, most likely binds
to a cavity between the TrpB active site and the COMM
domain, and shifts the latter into an unproductive extended-
open conformation. In this way, 4 e might also block the hy-
drophobic channel, which is located close to its binding site,
and thus impede indole transport from the TrpA active site to
the TrpB active site. As a result, the light-sensitive inhibition of
TS by 4 e is noncompetitive. Hence, a revision of our proposed
strategy of light-dependent inhibition of TS (Figure 2 C) was re-
quired.
In the absence of the inhibitor, the allosteric communication
between the TrpA and TrpB active sites can take place, activat-
ing the turnover of IGP in TrpA and serine in TrpB (Figure 6 A,
left panel). The E isomer of 4 e binds with high affinity to the
TrpB subunit and disturbs the allosteric communication by
shifting the COMM domain to the extended-open conforma-
tion, rendering TrpB, and most likely TrpA, inactive (Figure 6 A,
middle panel). As confirmed by inhibition studies, the Z
isomer, obtained by irradiation with UV light, has lower appar-
ent binding affinity and dissociates from the TrpB subunit.
Thus, the active, closed conformation of the COMM domain is
reconstituted, the allosteric communication is restored, and
TrpA and TrpB are both reactivated (Figure 6 A, right panel).
We further evaluated this sequence of events in an in situ ir-
radiation setup (Figure 6 B) by monitoring the activity of the
overall TS reaction in three samples. One reaction assay was
performed in the presence of inhibitor 4 e in its E configuration
in the dark (“dark”). The second assay was started in the pres-
ence of inhibitor 4 e in its E configuration, and then irradiated
during the initial linear activity phase of the enzyme (“direct
photocontrol”). Moreover, we applied the same treatment as
control to a reaction assay in the absence of 4 e (“uninhibit-
ed”). TS activity was inhibited approximately twofold by 4 e in
the dark and direct-photocontrol (prior to irradiation) samples
relative to the activity in the uninhibited sample. This con-
firmed the medium-strength inhibition effect observed in in-
hibitory studies and depicted in the middle panel of Figure 6 A.
On irradiation of the direct-photocontrol sample, the reaction
velocity increased 1.2-fold. This LRF is unexpectedly small and
disagrees with the LRF determined in Ki studies. However, TS
Figure 5. Identification of the 4 e binding site in TS. A) Mole2.5[32] analysis of TS4e (PDB-ID: 7A20) identified a pocket (gray mesh) between the TrpB active site
(marked with the bound buffer molecule in spheres) and the COMM domain (blue) that matches the dimensions of the inhibitor. Note: the cavity is only
shown for the chain pair CD; however, it also forms in the chain pair AB. B), C) Docking analysis with YASARA[33] demonstrated that 4 e (green) can bind in var-
ious orientations in the binding pocket identified in A) (black) ; two variations, which represent the binding orientations of cluster 1 (B) and cluster 3 (C), are
shown with their predicted KD values.
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activity in the absence of 4 e in our uninhibited sample was
decreased by a factor of 2.2 on irradiation with UV light. We
previously observed this effect during our studies on light con-
trol of TS with photosensitive unnatural amino acids,[24c] and
associated it with degradation of the light-sensitive PLP cofac-
tor. When we now consider this additional phototoxic effect,
light-induced isomerization of 4 e actually translates into a 2.6-
fold regulation of TS activity, approximating the LRF of about 5
in the Ki studies. This recovery of enzyme activity constitutes
the situation depicted in the right panel of Figure 6 A.
An LRF of 3–5 sets high expectations for the inhibitor’s
effect on bacterial growth. In general, photochromic inhibitors
of enzymes are often more convincing in vivo than in vitro.[17b]
This holds true particularly for enzymes in signaling cascades,
but also for antibacterial lead compounds, for which it could
be shown that an LRF of approximately two is sufficient to
control bacterial death with light.[34] The photocontrolled effect
of 4 e on the essential multi-enzyme complex TS of S. typhimu-
rium is therefore promising, but various improvements are nec-
essary before its efficacy against bacteria can be proved and
ultimately its antibiotic potential can be tested in vivo. First,
binding and inhibition strengths need to be increased to im-
prove the effectiveness of the inhibitor in biological systems.
For this, the structure of the azobenzene-based compound can
be customized for binding to the cavity between the TrpB
active site and the COMM domain. Motifs for the specific inter-
action with residues lining the cavity can be introduced into
the linker region or might replace it. Moreover, the irradiation
wavelength needs to be shifted towards higher regions of the
electromagnetic spectrum, for example, in the red region of
visible light, to increase the penetration depth of light and
minimize phototoxic effects on the tissue. The hazardous
effect of UV light was emphasized by the strong decrease of
TS activity after irradiation. The irradiation wavelength, PSD,
and thermal lifetime of the Z isomer can be optimized by in-
troducing suitable substituents[35] or by applying heteroaryl
design.[36] Ultimately, the photocontrollable inhibitor can be
deployed to tackle common drawbacks of customary antibiot-
ics. These are especially the collateral damage that they cause,
for example, by attacking pathogenic and nonpathogenic bac-
teria, and their permanent biological activity. As a conse-
quence, accumulation of these drugs in the environment pro-
motes the creation and rapid spreading of multiresistance in
bacterial strains.[37] Hence, a spatiotemporally restricted mode
of the antibacterial efficacy of antibiotics is desirable. Our in-
hibitor 4 e is not yet suited for this purpose, as the less inhibi-
tory Z isomer is also the thermally unstable one. Consequently,
the amount of the more-inhibitory E isomer would be in-
creased over time. However, by, for example, applying the
sign-inversion strategy the thermodynamic stability of the two
Figure 6. Activity modulation of TS by the photoswitchable noncompetitive inhibitor 4 e. A) Binding of 4 e in its E configuration (green rectangle) to TrpB
shifts the COMM domain to an extended-open conformation, which likely disrupts the allosteric activation between TrpA and TrpB and thus diminishes tryp-
tophan production from IGP (red ellipse) and Ser. On irradiation with UV light, the inhibitor is isomerized to its Z configuration (green elbow), which restores
TrpA and TrpB activity. This step is reversed by irradiation with visible light. B) Direct photocontrol of TS activity with 4 e (red) compared to a dark control
(kept in the dark; gray) and an uninhibited control (in the absence of 4 e, black). Reaction conditions: 50 mm potassium phosphate pH 7.5, 100 mm KCl, 5 mm
l-serine, 3.0 mm phenol, 3.0 mm 4-aminoantipyrine, 20 mm PLP, 0.075 g L1 HRP, 1.0 g L1 VioA, and, in the case of direct photocontrol and dark, 250 mm 4 e. All
three reactions were started with the TS complex (0.1 mm), monitored for approximately 30 min, irradiated for 15 s at 365 nm while enzyme velocity was still
in the initial linear range, and monitored further up to 50 min.
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photoisomers could be inverted to make the strongly inhibito-
ry E isomer the metastable form.[38]
Conclusion
Despite an urgent need, the search for new antibiotics was
only recently expanded to inhibitors that target metabolic en-
zymes or that can be controlled externally. Following this re-
search direction, we set out to explore the TS of S. typhimuri-
um as a potential antibiotic target enzyme by designing an in-
hibitor that can be controlled in a spatiotemporal manner by
light. Hence, we synthesized a small library of azobenzene-
based inhibitors towards the TrpA subunit. The compounds
can be reversibly switched in water up to approximately 90 %
of the photochemically generated isomer by using UV or blue
light. Inhibition studies quickly identified 4 e as the most prom-
ising TS inhibitor, as it provides exceptionally good solubility,
distinct photochromism, reasonable inhibition, and a pro-
nounced difference in inhibition strength between the photo-
isomers. This analysis also revealed a noncompetitive mode of
inhibition towards both the TrpA and TrpB active sites, a find-
ing contrary to our design. We consequently used a combina-
tion of ITC-based binding studies, crystallization experiments,
and computational analyses to unveil the potential binding
site of 4 e, which is a cavity at the TrpB subunit. Moreover,
structural analysis showed pronounced conformational
changes of the COMM domain, which adopted an allosterically
unproductive extended-open conformation. In further studies,
we aim to improve the design of this new lead compound,
taking the characteristics of its actual binding site into account,
and to optimize the photophysical and photochemical proper-
ties of the parent azobenzene. These findings are the starting
point to develop fully light-controllable TS inhibitors, which
can be further optimized into smart antibiotic agents.
Experimental Section
General information
Analytical samples of the alcohols and final compounds were puri-
fied by preparative HPLC [MeCN in H2O/0.05 % trifluoroacetic acid
(TFA) 5–100 % over 20 min] to give all compounds as orange
solids. NMR spectra were recorded with a Bruker Avance 400 MHz
NMR or a Bruker Avance 600 Kryo. Some of the alcohols partly de-
composed during the measurement. Thus, carbon signals were as-
signed by means of HSQC measurements (quaternary carbon
atoms could not be assigned in these cases). Due to the low reac-
tion yields, 13C NMR spectroscopy was not feasible for 4 a–d,f. A
description of the general working methods can be found in Sec-
tion 1 of the Supporting Information.
Synthesis
General procedure for amide formation : In a crimp-top vial, (E)-4-
(phenyldiazenyl)benzoic acid (1 equiv) was dissolved in SOCl2 (1 mL
per 200 mg). The suspension was heated to 80 8C for 2 h to give a
clear, red solution. The reaction mixture was cooled to ambient
temperature and the solvent was removed in vacuo. The vial was
flushed with vacuum/nitrogen three times and dry CHCl3 (5 mL)
was added under nitrogen atmosphere. Then, a solution of the re-
spective aniline (1 equiv) or amino alcohol (1 equiv), in dry pyridine
(1 mL) was added dropwise through a syringe. The solution was
stirred for 16 h and the solvent was removed in vacuo. The crude
product was purified by MPLC (20!100 % EtOAc in petroleum
ether).
(E)-N-(4-(2-hydroxyethyl)phenyl)-4-(phenyldiazenyl)benzamide (3 a):
(E)-4-(Phenyldiazenyl) benzoic acid (4.42 mmol) was employed.
Compound 3 a was obtained in 8 % yield (0.37 mmol). Rf (10 %
MeOH in CH2Cl2): 0.6.
1H NMR (300 MHz, 10 % CD3OD in CDCl3): d=
8.03 (d, J = 8.5 Hz, 2 H), 7.98–7.93 (m, 2 H), 7.92–7.89 (m, 2 H), 7.57
(d, J = 8.3 Hz, 2 H), 7.53–7.45 (m, 3 H), 7.19 (d, J = 8.4 Hz, 2 H), 3.76
(t, J = 6.9 Hz, 2 H), 2.80 (t, J = 6.9 Hz, 2 H). 13C NMR (151 MHz,
[D6]acetone): d= 132.0 (+), 130.3 (+), 130.1 (+), 129.6 (+), 123.8
(+), 123.4 (+), 121.1 (+), 64.0 (), 30.4 (). Assignment was based
on HSQC measurements due to low concentrations and lability of
the compound. Thus, quaternary carbon atoms could not be as-
signed. IR: ñ= 3351(m), 3045 (w), 2926 (w), 2863 (w), 1648 (s), 1520
(s), 1051 (m), 861 (m), 820 (m), 771 (m), 686 cm1 (m). ESI-MS:
calcd: 345.1477, found: 713.3 (2MNa+ , 5 %; 368.1 MNa+ , 10 %;
346.2 MH+ , 100 %). HRMS (ESI): found: 368.1373 (MNa+ , 15 %),
346.1559 (MH+ , 100 %).
(E)-N-(2-hydroxyethyl)-4-(phenyldiazenyl)benzamide (3 b): (E)-4-(Phe-
nyldiazenyl)benzoic acid (4.42 mmol) was employed. Compound
3 b was obtained in 31 % yield (1.39 mmol). Rf (10 % MeOH in
CH2Cl2): 0.5.
1H NMR (400 MHz, [D6]acetone): d= 8.10–8.05 (m, 2 H),
7.98–7.90 (m, 4 H), 7.60–7.51 (m, 3 H), 3.68 (t, J = 5.7 Hz, 2 H), 3.50
(q, J = 5.6 Hz, 2 H). 13C NMR (151 MHz, [D6]acetone): d= 129.5 (+),
129.2 (+), 128.2 (+), 122.7 (+), 122.3 (+), 60.8 (), 42.5 (). Assign-
ment was based on HSQC measurements due to low concentra-
tions and decomposition of the compound during the extended
measuring time. Thus, quaternary carbon atoms could not be as-
signed. IR: ñ= 3258 (w), 3064 (w), 3926 (w), 1722 (m), 1626 (m),
1268 (s), 1092 (m), 857 (m), 686 cm1 (s). ESI-MS: calculated:
269.1164, found: 561.2 (2MNa+ , 20 %), 292.1 (MNa+ , 20 %), 270.1
(MH+ , 100 %). HRMS (ESI): found: 292.1062 (MNa+ , 20 %), 270.1242
(MH+ , 100 %).
(E)-N-(3-hydroxypropyl)-4-(phenyldiazenyl)benzamide (3 c): (E)-4-(Phe-
nyldiazenyl)benzoic acid (2.10 mmol) was employed. Compound
3 c was obtained in 10 % yield (0.22 mmol). Rf (10 % MeOH in
CH2Cl2): 0.5.
1H NMR (400 MHz, [D6]acetone): d= 8.16–8.06 (m, 2 H),
8.03–7.87 (m, 4 H), 7.75–7.47 (m, 3 H), 3.64 (t, J = 6.0 Hz, 2 H), 3.55
(q, J = 6.5 Hz, 2 H), 1.80 (p, J = 6.3 Hz, 2 H). 13C NMR (101 MHz,
[D6]acetone): d= 166.1 (q), 153.9 (q), 152.5 (q), 137.1 (q), 131.7 (+),
129.3 (+), 128.3 (+), 122.8 (+), 122.5 (+), 59.1 (), 36.9 (), 32.5
(). IR: ñ= 3368 (w), 3291 (m), 3060 (w), 2937 (w), 2881 (w), 1627
(s), 1536 (s), 1073 (m), 775 (m), 686 (s). ESI-MS: calculated:
283.1324, found: 306.1 (MNa+ , 20 %), 284.1 (MH+ , 100 %). HRMS
(ESI): found: 306.1215 (MNa+ , 20 %), 284.1401 (MH+ , 100 %).
(E)-N-(4-hydroxybutyl)-4-(phenyldiazenyl)benzamide (3 d): (E)-4-(Phe-
nyldiazenyl)benzoic acid (2.21 mmol) was employed. Compound
3 d was obtained in 3 % yield (0.06 mmol). Rf (10 % MeOH in
CH2Cl2): 0.5.
1H NMR (400 MHz, [D6]acetone): d= 8.11–8.06 (m, 2 H),
7.99–7.93 (m, 4 H), 7.63–7.55 (m, 3 H), 3.59 (t, J = 6.2 Hz, 2 H), 3.51–
3.39 (m, 2 H), 1.78–1.66 (m, 2 H), 1.66–1.55 (m, 2 H). 13C NMR
(101 MHz, [D6]acetone): d= 165.5 (q), 153.8 (q), 152.5 (q), 137.4 (q),
131.7 (+), 130.8 (+), 129.3 (+), 128.2 (+), 122.8 (+), 122.4 (+), 61.3
(), 39.6 (), 30.2 (), 26.2 (). IR: ñ= 3321 (w), 3045 (w), 2926 (w),
2862 (w), 1647 (s), 1521 (s), 861 (m), 820 (s), 771 (s), 865 cm1 (s).
ESI-MS: calculated: 297.1477, found: 617.3 (2MNa+ , 40 %), 320.1
(MNa+ , 20 %), 298.2 (MH+ , 100 %). HRMS: 320.1376 (MNa+ , 40 %),
298.1559 (MH+ , 100 %).
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(E)-N-(5-hydroxypentyl)-4-(phenyldiazenyl)benzamide (3 e): (E)-4-(Phe-
nyldiazenyl)benzoic acid (1.33 mmol) was employed. Compound
3 e was obtained in 5 % yield (0.07 mmol). Rf (10 % MeOH in
CH2Cl2): 0.8.
1H NMR (400 MHz, [D6]acetone): d= 8.11–8.05 (m, 2 H),
7.99–7.94 (m, 4 H), 7.63–7.56 (m, 3 H), 3.54 (t, J = 6.3 Hz, 2 H), 3.47–
3.40 (m, 2 H), 1.65 (p, J = 7.2 Hz, 2 H), 1.59–1.51 (m, 2 H), 1.51–1.42
(m, 2 H). 13C NMR (151 MHz, [D6]acetone): d= 130.2 (+), 129.3 (+),
128.2 (+), 122.8 (+), 122.4 (+), 62.3 (), 40.5 (), 33.4 (), 29.4 (),
24.1 (). Assignment was based on HSQC measurements due to
low concentrations and decomposition of the compound during
the extended measuring time. Thus, quaternary carbon atoms
could not be assigned. IR: ñ= 3295 (w), 3052 (w), 2933 (w), 2870
(w), 1714 (s), 1629 (s), 1536 (s), 1271 (s), 1119 (m), 775 (s), 686 (s).
ESI-MS: calculated: 311.1634, found: 312.2 (MH+ , 100 %). HRMS:
334.1531 (MNa+ , 40 %), 312.1712 (MH+ , 100 %).
(E)-N-(6-hydroxyhexyl)-4-(phenyldiazenyl)benzamide (3 f): (E)-4-(Phe-
nyldiazenyl) benzoic acid (4.32 mmol) was employed. 3 a was ob-
tained in 2 % yield (0.07 mmol). Rf (10 % MeOH in CH2Cl2): 0.5.
1H NMR (400 MHz, [D6]acetone): d= 8.10–8.06 (m, 2 H), 8.00–7.93
(m, 4 H), 7.65–7.53 (m, 3 H), 3.53 (t, J = 6.4 Hz, 2 H), 3.43 (td, J = 7.2,
5.8 Hz, 2 H), 1.64 (p, J = 7.1 Hz, 2 H), 1.56–1.48 (m, 2 H), 1.45–1.36
(m, 4 H). 13C NMR (151 MHz, [D6]acetone): d 152.8 (+), 152.5 (+),
131.7 (+), 129.3 (+), 128.3 (+), 122.8 (+), 122.4 (+), 62.4 (), 40.6
(), 33.8 (), 30.7 (), 30.6 (), 27.2 (). Assignment was based on
HSQC measurements due to low concentrations and decomposi-
tion of the compound during the extended measuring time. Thus,
quaternary carbon atoms could not be assigned. IR: ñ= 3384 (w),
3295 (m), 2937 (m), 2855 (m), 1627 (s), 1531 (s), 1297 (m), 858 (m),
775 (s), 686 cm1 (s). ESI-MS: calculated: 325.1790, found: 673.3
(2MNa+ , 25 %), 348.2 (MNa+ , 35 %), 326.2 (MH+ , 100 %). HRMS:
348.1687 (MNa+ , 20 %), 326.1869 (MH+ , 100 %).
Phosphorylation
General procedure I for phosphorylation : An oven-dried crimp-
top vial was loaded with compound 3 a,b,d,f (1 equiv), proton
sponge (3 equiv), and a stirring bar, and sealed. The vial was
purged with vacuum/nitrogen (3  each) before dry CHCl3 (1 mL
per 0.15 mmol) was added. The reaction mixture was cooled to
0 8C and POCl3 in dry THF (1:2, 0.5 mL per 0.15 mmol) was added
dropwise via syringe. Then, the mixture was allowed to warm to
ambient temperature and was stirred for 2 h. After quenching with
acetone/water (1:1), the solvent was removed in vacuo and the
crude product was purified through preparative HPLC (MeCN in
H2O/0.05 % TFA, 5!95 %). The products were obtained as orange
powders after lyophilization.
General procedure II for phosphorylation : An oven-dried crimp-
top vial was equipped with compound 3 c,e (1 equiv), proton
sponge (3 equiv), and a stirring bar, and sealed. The vial was
purged with vacuum/nitrogen (3  each) before PO(OMe)3 (1 mL
per 0.15 mmol) was added. The reaction mixture was cooled to
0 8C and POCl3 (0.5 mL per 0.15 mmol) was added dropwise by sy-
ringe. Then, the mixture was allowed to warm to ambient temper-
ature and was stirred for 2 h. After quenching with acetone/water
(1:1), the solvent was removed in vacuo and the crude product
was purified by preparative HPLC (MeCN in H2O/0.05 % TFA, 5!
95 %). The products were obtained as orange powders after lyophi-
lization.
(E)-4-(4-(phenyldiazenyl)benzamido)phenethyl dihydrogenphosphate
(4 a): Compound 3 a (125 mg, 0.36 mmol) was employed. Com-
pound 4 a was obtained in 0.5 % yield (0.8 mg, 0.002 mmol). HPLC:
Rt = 15.7 min, >99 % purity (220 nm), 96 % purity (254 nm trace).
1H NMR (400 MHz, CD3ODCD3OD): d= 8.11 (d, J = 8.5 Hz, 2 H), 8.02
(d, J = 8.5 Hz, 2 H), 7.96 (dd, J = 7.9, 1.9 Hz, 2 H), 7.65 (d, J = 8.3 Hz,
2 H), 7.60–7.54 (m, 3 H), 7.30 (d, J = 8.4 Hz, 2 H), 4.14 (q, J = 7.0 Hz,
2 H), 2.98 (t, J = 7.0 Hz, 2 H). 31P NMR (162 MHz, CD3OD): d= 0.00. IR:
ñ= 2922 (w), 2662 (w), 1647 (m), 1524 (m), 1062 (s), 771 (s), 686 (s).
ESI-MS: calculated: 425.1141, found: 426.1 (MH+ , 55 %), 380.1
(50 %), 346.2 (100 %), 309.1 (50 %), 224.1 (30 %); found: 424.1
((MH) , 100 %), 344.1 (30 %). HRMS: 426.1210 (MH+ , 100 %),
424.1079 ((MH) , 100 %).
(E)-2-(4-(phenyldiazenyl)benzamido)ethyl dihydrogen phosphate (4 b):
Compound 3 b (374 mg, 1.38 mmol) was employed. 4 b was ob-
tained in 0.2 % yield (1.2 mg, 0.003 mmol). 1H NMR (400 MHz,
CD3OD): d= 8.07–7.89 (m, 6 H), 7.62–7.48 (m, 6 H), 3.79–3.69 (m,
4 H). 31P NMR (162 MHz, CD3OD): d=0.00. ESI-MS: calculated:
349.0828. found: 348.1 ((MH) , 100 %). IR: ñ= 3299 (w), 2963 (w),
2930 (w), 1629 (s), 1536 (s), 861 (s), 775 (s), 686 (s).
(E)-3-(4-(phenyldiazenyl)benzamido)propyl dihydrogen phosphate
(4 c): Compound 3 c (63 mg, 0.22 mmol) was employed. Compound
4 c was obtained in 7 % yield (5.3 mg, 0.02 mmol). HPLC: Rt =
18.1 min, 95 % purity (220 and 254 nm). 1H NMR (400 MHz, CD3OD):
d= 8.69 (s, 0 H), 8.08–7.89 (m, 1 H), 7.69–7.41 (m, 1 H), 3.67 (t, J =
6.5 Hz, 0 H), 3.56 (tt, J = 6.9, 2.9 Hz, 0 H), 2.10 (p, J = 6.7 Hz, 0 H).
31P NMR (162 MHz, CD3OD). d= 0.00. IR: ñ= 3317 (w), 3079 (w),
2937 (w), 2463 (w), 1625 (m), 1543 (m), 1442 (m), 1286 (m), 857
(m), 775 (s), 686 (s). ESI-MS: calculated: 347.3108. found: 346.1
((MH) , 100 %).
(E)-4-(4-(phenyldiazenyl)benzamido)butyl dihydrogen phosphate (4 d):
Compound 3 d (293 mg, 0.99 mmol) was employed. Compound 4 d
was obtained in 4 % yield (14.7 mg, 0.04 mmol). HPLC: Rt =
18.7 min, 97 % purity (220 nm), 95 % purity (254 nm). 1H NMR
(400 MHz, CD3OD): d= 8.18–8.06 (m, 4 H), 8.03–7.96 (m, 2 H), 7.63–
7.56 (m, 3 H), 4.90 (t, J = 5.4 Hz, 2 H), 3.80 (t, J = 6.0 Hz, 2 H), 2.46–
2.32 (m, 2 H). 31P NMR (162 MHz, CD3OD): d= 0.00. IR: ñ= 3414 (w),
3029 (w), 1662 (s), 1275 (m), 1178 (s), 1115 (s), 690 (s). ESI-MS: cal-
culated: 377.1141, found: 378.1 (MH+ , 100 %), 247.3 (80 %), 223.1
(30 %); found: 376.1 ((MH) , 100 %). HRMS: 378.1215 (MH+ ,
100 %), 376.1078 ((MH) , 100 %).
(E)-5-(4-(phenyldiazenyl)benzamido)pentyl dihydrogen phosphate
(4 e): Compound 3 e (184 mg, 0.59 mmol) was employed. Com-
pound 4 e was obtained in 37 % yield (86.7 mg, 0.22 mmol). HPLC:
Rt = 13.4 min, 98 % purity (220 nm), <99 % purity (254 nm).
1H NMR
(400 MHz, CD3OD): d= 8.04–7.73 (m, 6 H), 7.51–7.12 (m, 3 H), 3.89
(q, J = 6.5 Hz, 2 H), 3.30 (t, J = 7.1 Hz, 2 H), 1.70–1.48 (m, 4 H), 1.40–
1.28 (m, 2 H). 13C NMR (101 MHz, CD3OD): d= 168.0 (q), 154.1 (q),
152.5 (q), 136.4 (q), 131.5 (+), 129.0 (+), 128.0 (+), 122.6 (+), 122.4
(+), 66.2 (), 39.6 (), 29.8 (), 28.6 (), 22.7 ().31P NMR
(162 MHz, CD3OD): d= 0.16. IR: ñ= 3313 (w), 3049 (w), 2930 (w),
2860 (w), 1643 (m), 1525 (m), 1010 (s), 771 (s), 686 (s). ESI-MS: cal-
culated: 391.1297, found: 390.1 ((MH) , 90 %), 269.1 (100 %).
HRMS: 392.1372 (MH+ , 100 %).
(E)-6-(4-(phenyldiazenyl)benzamido)hexyl dihydrogenphosphate (4 f):
Compound 3 f (24 mg, 0.074 mmol) was employed. Compound 4 f
was obtained in 7 % yield (1.9 mg, 0.005 mmol). HPLC: Rt =
14.0 min, 95 % purity (220 nm), <99 % purity (254 nm). 1H NMR
(400 MHz, CD3OD): d= 8.02–7.92 (m, 6 H), 7.60–7.51 (m, 3 H), 3.97
(q, J = 6.6 Hz, 2 H), 3.41 (t, J = 7.1 Hz, 2 H), 1.68 (dp, J = 13.7, 6.8 Hz,
4 H), 1.46 (dd, J = 7.9, 4.4 Hz, 4 H). 31P NMR (162 MHz, CD3OD): d=
0.30. IR: ñ= 3314 (w), 2930 (m), 2855 (m), 1625 (m), 1536 (m), 1014
(s), 775 (s). ESI-MS: calculated: 405.1454, found: 406.2 (MH+ , 25 %),
274.3 (100 %), 214.1 (90 %); found: 404.1 ((MH) , 100 %). HRMS:
406.1526 (MH+ , 100 %), 404.1388 ((MH) , 100 %).
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Photophysical and photochemical characterization
UV/Vis absorption spectra of compounds 4 a–f were recorded with
a JASCO V-650 spectrophotometer. Compound 4 c and the thermal
lifetime of compound 4 e were analyzed with an Agilent 8453 spec-
trometer. For temperature control, a Varian Cary single-cell Peltier
apparatus was used. The used solvent and concentration are
stated for each experiment. UV-induced isomerization reactions
were performed with a Soul Veasos single-spot LED (365 nm,
0.9 W), an OSRAM Oslon SSL 80 single-spot LED (455 nm, 1.2 W), or
a Sylvania UV lamp with two 8 W fluorescent black-light bulbs (set-
tings: 250 mA, 220 V). Sample volume was 1 mL. For direct pho-
tocontrol experiments, 4 e was isomerized by using a high-power
LED (LED Engin, Osram; settings: 700 mA and 16 V) for 15 s. The
sample volume was 200 mL.
Bacterial strains, plasmids, and chemicals
The proteins used in this work were produced in the E. coli expres-
sion strains E. coli BL21 Gold (DE3) (purchased from Agilent Tech-
nologies, Santa Clara, CA, USA) and E. coli BL21 (DE3) Rosetta (pur-
chased from Novagen, Merck, Darmstadt, Germany). The following
expression plasmids were taken from previously published work:
pET28a TrpA, pET24a TrpB, and pET28a VioA.[24c] HRP was pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). IGP was produced
enzymatically from 1-(o-carboxyphenylamino)-1-deoxyribulose-5-
phosphate as described previously.[39] All other chemicals were pur-
chased form commercial sources and were of analytical grade or
higher.
Expression and purification of TS
The genes coding for TrpA and TrpB were heterologously ex-
pressed in BL21 (DE3) Rosetta and BL21 Gold (DE3), respectively.
Cells containing expression vectors with the respective genes were
grown at 37 8C to an OD600 of 0.6 in 2–6 L lysogeny broth (LB)
medium supplemented with kanamycin. At this point, 0.5 mm iso-
propyl-b-d-thiogalactopyranosid (IPTG) was added to induce gene
expression and cells were incubated overnight at 20 8C. The cells
were harvested by centrifugation, resuspended in 100 mm potassi-
um phosphate (KP) pH 7.5, 300 mm KCl, 20 mm imidazole (20 mL
per 1 L cell suspension), and disrupted by sonication. Cell debris
and insoluble aggregates were removed by centrifugation. Proteins
were purified from the supernatant by nickel-affinity chromatogra-
phy (HisTrap FF Crude column, 5 mL, GE Healthcare) with a linear
gradient of imidazole (20 mm!500 mm) followed by size-exclusion
chromatography (Superdex 75 HiLoad 26/600, GE Healthcare, Chi-
cago, IL, USA) using 100 mm KP pH 7.5, 300 mm KCl as buffer. Frac-
tions containing the purified protein were pooled and dripped into
liquid nitrogen for storage at 80 8C.
Expression and purification of auxiliary enzymes
The auxiliary enzyme tryptophan oxidase (VioA) from Chromobacte-
rium violaceum was expressed in BL21 Gold (DE3).[24c] Transformed
E. coli strains were grown in 4L LB medium supplemented with ka-
namycin at 37 8C to an OD600 of 0.6. Then, protein expression was
induced with 0.5 mm IPTG and cells were incubated overnight at
20 8C. Cells were harvested by centrifugation and the pellets were
resuspended in 20 mm Tris·HCl pH 8.0, 300 mm NaCl, and 20 mm
imidazole. The target protein was obtained from the supernatant
after sonication and repeated centrifugation steps. VioA was cap-
tured by nickel-affinity chromatography (HisTrap FF Crude column,
5 mL, GE Healthcare, Chicago, IL, USA) and eluted with a linear gra-
dient of imidazole (10!500 mm). Fractions containing the target
protein were identified by SDS-PAGE analysis, pooled, and further
purified by size-exclusion chromatography (Superdex 75 HiLoad
26/600, GE Healthcare, Chicago, IL, USA) with 20 mm Tris·HCl
pH 8.0 as running buffer. Fractions containing the purified protein
were pooled and dripped into liquid nitrogen for storage at
80 8C.
Steady-state activity measurements and inhibition studies
In general, steady-state enzyme kinetic measurements were per-
formed at 25 8C and monitored spectrophotometrically by using a
microplate reader (Infinite M200 Pro, TECAN, Mnnedorf, Switzer-
land). Turnover of IGP or indole to Trp was measured with a cou-
pled enzymatic assay,[24c] employing VioA, which oxidized Trp to
produce the side-product peroxide, and horseradish peroxidase
(HRP), which then turned over peroxide with 4-aminoantipyrine
and phenol to water and a quinone imine. Formation of the
latter was monitored at 505 nm (De505 (quinone imine) =
6,400 m1 cm1).[40] All reactions were started by addition of the TS
complex in 1:1 stoichiometry. Reaction conditions were: 50 mm KP,
pH 7.5, 100 mm KCl, 5 mm Ser, 1.0 mm phenol, 1 mm 4-aminoanti-
pyrine, 20 mm pyridoxal phosphate (PLP), 0.15 g L1 horseradish
peroxidase (HRP), 1.0 g L1 VioA, and varying concentrations of sub-
strate (0–200 mm for indole, 0–150 mm for IGP). In order to deter-
mine turnover rates, the initial slopes vi of the substrate turnover
curves were measured and divided by the total enzyme concentra-
tion [Et] . These turnover rates vi/[Et] (in s
1) were plotted against
the substrate concentration [S] . Michaelis–Menten constants KM
and turnover numbers kcat were determined by fitting the data
with Equation (1)[28] by using Origin 2019 (OriginLab).
vi
Et½ 
¼ kcat S½ 
K M þ S½ 
ð1Þ
To identify the concentration range in which the azobenzenze-
based compounds inhibited TS, activity measurements were per-
formed with varying inhibitor concentrations and constant IGP and
Ser concentrations. Reaction conditions were: 50 mm KP, pH 7.5,
100 mm KCl, 5 mm Ser, 1.0 mm phenol, 1.0 mm 4-aminoantipyrine,
20 mm PLP, 0.15 g L1 HRP, 1.0 g L1 VioA, 30 mm IGP, and 0–300 mm
4 d–f. Reactions were performed at 25 8C. After baseline detection,
the reactions were started by addition of the 0.1 mm TS complex in
1:1 TrpA:TrpB stoichiometry. All measurements were performed by
using a microplate reader (Infinite M200 Pro, TECAN, Mnnedorf,
Switzerland). The initial reaction rates for different inhibitor con-
centrations were normalized to the reaction rate in the absence of
inhibitor, and plotted against the logarithm of the inhibitor con-
centration.
To determine the mode of inhibition, steady-state kinetics were re-
corded for four different inhibitor concentrations, which corre-
sponded to degrees of inhibition of 0 % (0 mm), 30 % (100 mm),
50 % (175 mm), and 70 % (250 mm), as measured in the previ-
ous setup. Reaction conditions were: 50 mm KP pH 7.5, 100 mm
KCl, 5 mm l-serine, 1.0 mm phenol, 1.0 mm 4-aminoantipyrine,
20 mm PLP, 0.15 g L1 HRP, 1.0 g L1 VioA, and varying concentra-
tions of substrate (0–150 mm for IGP and 0–200 mm for indole). Re-
actions were started by addition of 0.1 mm TS complex in 1:1
TrpA:TrpB stoichiometry. Fitting the data of a single kinetic experi-
ment to the Michaelis–Menten equation [Eq. (1)] provided an ap-
parent rate constant kappcat and the apparent Michaelis constant K
app
M .
The values of the inhibition constant Ki and the a value, which de-
scribes the mode of inhibition, were determined by using a gener-
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al model for enzyme inhibition.[28] For this, the steady-state kinetic
data in presence of inhibitor was evaluated by plotting the mea-
sured reaction rates vi divided by the total enzyme concentration
[Et] against the substrate concentration [S] . The values for kcat, KM,
Ki, and a were determined by a global fit of the four inhibition
curves for the four inhibitor concentrations [I] with Equation (2).[28]
vi
Et½ 
¼ kcat S½ 
S½  1þ I½ aK i
 
þ K M 1þ I½ K i
  ð2Þ
Competitive inhibition is characterized by an infinite a value (a!
1), because there is no binding of the inhibitor to the enzyme:-
substrate (ES) complex. Uncompetitive inhibition leads to an a
value close to zero (a ! 1), because there is no binding to the free
enzyme.[28] In noncompetitive inhibition, there is affinity for both
the ES complex and the free enzyme, which is characterized by a
finite value of a.
Determination of binding constants
Binding constants were determined by means of ITC measure-
ments with a MicroCal PEAQ-ITC system (Malvern). Solutions of
protein (50–100 mm) and 4 e (1.0 mm) were prepared by using the
same buffer stock (300 mm Tris·HCl, pH 8.0). Three control ex-
periments, namely the titration of buffer with buffer, the titration
of protein solution with buffer, and the titration of buffer with
ligand, were performed. Each titration experiment was baseline
corrected and the signal peaks of each injection were integrated
by MicroCal PEAQ-ITC analysis (version 1.22, Malvern Panalytical).
Then, each protein–ligand titration experiment was corrected for
each control experiment and processed by using the built-in func-
tions of MicroCal PEAQ-ITC analysis with the “single set of identical
sites” option. Thus, a DH versus molar ratio (ligand:protein) plot
and fit values for the binding constant KD, the number of binding
sites n, and the molar heat of ligand binding DH were obtained.
The fitted number of binding sites in initial analyses was close to
one. For better comparability, the number of binding sites was
then set to one for all experiments.
Crystallization
Tryptophan synthase was cocrystallized with ligand 4 e by using
the hanging-drop vapor-diffusion method. For this, TrpA and TrpB
were complexed in equimolar amounts and supplemented with a
twofold excess of ligand 4 e to final concentrations of 30 g L1 TS
complex and 750 mm ligand 4 e in 50 mm Tris·HCl pH 7.5. Then,
1 mL of the mixture was mixed with 1 mL of reservoir solution con-
taining 7 % PEG 8000 and 0.1 m sodium citrate, pH 5. Crystals grew
within several weeks in a rod-like morphology. Crystals were
mounted on a nylon loop and shock-frozen in liquid nitrogen with-
out addition of further cryoprotectants.
Identification of tunnels with MOLE 2.5
To find cavities in the crystal structure of TS4e, the graphical user in-
terface of MOLE 2.5.17.4.24 was used. The structure of TS4e was
loaded into the program and tunnels were identified by applying
the automated built-in protocol with default parameter settings,
that is, a bottleneck radius of 1.25 , an origin radius of 5.00 , a
surface cover radius of 10.00 , a bottleneck length of 0.00 , a
cutoff ratio of 0.90, a minimum tunnel length of 0.00 , and a mini-
mum pore length of 0.00 . The default weight function was the
Voronoi scale. Note: we use the term “cavity” for the identified
pocket, whereas Mole 2.5 uses the term “tunnel”.
Docking with YASARA
Compound 4 e was docked to TrpB by VINA docking[41] as imple-
mented in YASARA, by utilizing the YASARA2 force field.[33] For this,
TrpB residues 85, 87, 109, 112, 114, 115, 166, 190, 350, 379, and 382
that surround the binding site were set as flexible. Compound 4 e
was docked 100 times to different TrpB conformations and the re-
sults were sorted according to their estimated binding energies.
Additionally, these poses were clustered into 17 distinct complex
conformations that had a distance of at least 5  deduced as root
mean square deviation of the heavy atoms of 4 e. Moreover, check-
ing the planarity of the azobenzene moiety after each docking run
confirmed that the integrity of the ligand was constantly pre-
served.
In situ irradiation
Reaction conditions for the direct photocontrol of enzymatic turn-
over included 50 mm KP pH 7.5, 100 mm KCl, 5 mm Ser, 1.0 g L1
VioA, 0.075 g L1 HRP, 100 mm IGP, 1.0 mm 4-aminoantipyrine,
1.0 mm phenol, 20 mm PLP, 200 mm 4 e, and 0.1 mm TS complex.
The reaction was started by the addition of the 0.1 mm TS complex
in 1:1 stoichiometry and monitored at l= 505 nm with De505 (qui-
none imine) = 6400 m1 cm1.[40] Measurements were performed in
a plate reader (Tecan Infinite M200 Pro) and activities were de-
duced from the slopes of the transition curves. Altogether two
samples and two controls were measured simultaneously. The reac-
tion rate of the first sample was monitored in the dark. The second
sample was irradiated during the initial linear-activity phase. Con-
trol experiments were performed either in the absence of 4 e or
with buffer instead of TS complex. Irradiation of the second
sample and the two controls was carried out by pausing the mea-
surement in the plate reader, taking out the plate, and exposing
the three wells to UV light, while keeping the other well (posi-
tioned furthest away), containing the first sample, covered. The
samples were irradiated after 30 min for 15 s with 365 nm (Mouser,
high-power LED, 365 nm, 1.7 V, 700 mA), which corresponded to
the irradiation time necessary for Z!E isomerization under these
conditions. The turnover curves of the irradiated second sample
and control sample in the absence of 4 e were baseline-corrected
by subtraction of the buffer control. The first sample was baseline
corrected by subtraction of a linear fit of the first 20 min of the
buffer control.
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Banš, C.-M. Ionescu, M. Otyepka, J. Koča, J. Cheminf. 2013, 5, 39.
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